Evidence map›Paper›PMID 12140761›Full record

ArticleOncogene2002

Human rgr: transforming activity and alteration in T-cell malignancies.

Peter Leonardi, Ezra Kassin, Inmaculada Hernandez-Muñoz, Roberto Diaz, Giorgio Inghirami, Angel Pellicer

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. RalA is overactivated in medulloblastoma.Journal of neuro-oncology · 2016
    Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Peter LeonardiDepartment of Pathology, 550 First Ave., New York University Medical Center, New York, NY 10016, USA.
Ezra Kassin
Inmaculada Hernandez-Muñoz
Roberto Diaz
Giorgio Inghirami
Angel Pellicer
The Netherlands Cancer Institute · NL

Funding

RGR--A NOVEL ONCOGENE IN THE RAL PATHWAYR01CA050434 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PELLICER, ANGEL · 1989 to 2002
$796k
NCI NIH HHS CA50434
6 · The paper itself

Abstract

We have previously identified the oncogene rgr (ralGDS related) in DNA derived from a rabbit squamous cell carcinoma. Here we describe the identification of the human orthologue of the rabbit rgr gene termed hrgr (human ralGDS related). Four alternatively spliced full-length hrgr transcripts were isolated from normal human testes and liver libraries. Truncation of hrgr confers transforming ability to its cDNA. Using a RT-PCR assay we have been able to detect the expression of an abnormally truncated transcript in several human T-cell lymphoma lines, and in fresh tissue samples of patients with T-cell malignancies. In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearrangement was detected within the hrgr gene region. We propose that these T-cell lymphomas, at least in part, owe their malignant phenotypes to genetic alterations of the hrgr gene. These findings also raise the possibility that mutations in the hrgr gene are involved in other malignancies.

Indexed as

Cell Transformation, Neoplastic3T3 CellsAlternative SplicingAmino Acid SequenceAnimalsBase SequenceCloning, MolecularHumansJurkat CellsLymphoma, T-CellMaleMiceMolecular Sequence DataOncogene ProteinsPhysical Chromosome Mappingral Guanine Nucleotide Exchange FactorOncogene Proteinsral Guanine Nucleotide Exchange FactorRNA, Messenger

Identifiers

PMID12140761
OpenAlexW2319514008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.